MARIZYME, INC. 8-K

What Happened

• Marizyme, Inc. announced that on April 9, 2026 its board determined a transfer of all or substantially all of the company’s assets via an assignment for the benefit of creditors was in the company's best interests. The company executed a general Assignment for the Benefit of Creditors on April 14, 2026 with Peter Hurwitz named as assignee.

Key Details

• Board action date: April 9, 2026; Assignment executed: April 14, 2026.
• Transaction: general assignment for the benefit of creditors to transfer all or substantially all assets to an assignee (Peter Hurwitz).
• Filing: Assignment Agreement is included as Exhibit 10.1 to the Form 8‑K; certain schedules were omitted from the public filing per Regulation S‑K and can be furnished to the SEC on request.

Why It Matters

• An assignment for the benefit of creditors is a formal process to transfer the company’s assets to an assignee for distribution to creditors. For investors, this filing signals a material disposition of assets and a significant change in the company’s status; stakeholders should expect communications from the company or the assignee about creditor claims, asset sales, and any potential distributions.